A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with
azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).